drugset / Trial / NCT00153907

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

NCT00153907

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine given with oral navelbine to patients with advanced breast cancer.

Timeline

Start
2002-03
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject Vinorelbine Small molecule Oral

Indications